Infliximab in the treatment of extra‐intestinal manifestations of Crohn's disease

References

• Greenstein A., Janowitz H., Sachar D. Extra‐intestinal complications of Crohn's disease and ulcerative colitis. Medicine 1976; 55: 401–12
   PubMed Web of Science ®Google Scholar
• Bernstein C. N., Blanchard J. F., Rawsthorne P., Yu N. The prevalence of extra‐intestinal disease in inflammatory bowel disease: a population based study. Am J Gastroenterol 2001; 96: 1116–22
   PubMed Web of Science ®Google Scholar
• Gravallese E. M., Kantrowitz F. G. Arthritic manifestations of inflammatory bowel disease. Am J Gastroenterol 1988; 83: 703–9
   PubMed Web of Science ®Google Scholar
• Orchard T. R., Thiyagaraja S., Welsh K. I., Wordsworth B. P., Hill Gaston J. S., Jewell D. P. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000; 118: 274–8
   PubMed Web of Science ®Google Scholar
• Orchard T. R., Chua C. N., Ahmad T., Cheng H., Welsh K. I., Jewell D. P., et al. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA. Gastroenterology 2002; 123: 714–18
   PubMed Web of Science ®Google Scholar
• Clegg D. O., Reda D. J., Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of seronegative spondyloarthropathies: A Department of Veterans Cooperative Study. Arthritis Rheum 1999; 42: 2325–9
   PubMed Web of Science ®Google Scholar
• Futami H., Kodaira M., Furuta T., Hanai H., Kaneko E. Pyoderma gangrenosum complicating ulcerative colitis: successful treatment with methylprednisolone pulse therapy and cyclosporine. J Gastroenterol 1998; 33: 408–11
   PubMed Web of Science ®Google Scholar
• Sampaio‐Barros P. D., Costallat L. T., Bertolo M. B. Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2000; 29: 160–2
   PubMed Web of Science ®Google Scholar
• Rankin G. B., Watts H. D., Melnyk C. S., Kelley M. L Jr. National Cooperative Crohn's Disease Study: extra‐intestinal manifestations and perianal complications. Gastroenterology 1979; 77: 914–20
   PubMed Web of Science ®Google Scholar
• Bernstein C. N. Treatment of extra‐intestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 2002; 4: 513–16
   PubMedGoogle Scholar
• Hanauer S. B., Feagan B. G., Lichtenstein G. R., Mayer L. F., Schreiber S., Colombel J. F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–9
   PubMed Web of Science ®Google Scholar
• Sands B. E., Anderson F. H., Bernstein C. N., Chey W. Y., Feagan B. G., Fedorak R. M., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 934–6
   PubMed Web of Science ®Google Scholar
• Van den Bosch F., Kruithof E., De Vos M., De Keyser F., Mielants H. Crohn's disease associated with spondyloarthropathy: effect of anti TNF‐alpha blockade with infliximab on articular symptoms. Lancet 2000; 356: 1821–2
   PubMed Web of Science ®Google Scholar
• Herfarth H., Obermeier F., Andus T., Rogler G., Nikolaus S., Kuehbacher T., et al. Improvement of arthritis an arthralgias after treatment with infliximab (Remicade) in a German prospective, open‐label, multicenter trial in refractory Crohn's disease. Am J Gastroenterol 2002; 10: 2688–90
   Google Scholar
• Rispo A., Lembo G., Insabato L., Cozzolino A., Pesce G., Castiglione F. Successful treatment of therapy‐resistant metastatic Crohn's disease with infliximab. Br J Dermatol 2004; 150: 1045–6
   PubMed Web of Science ®Google Scholar
• Murphy C. C., Ayliffe W. H., Booth A., Makanjuola D., Andrews P. A., Jayne D. Tumor necrosis alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004; 111: 352–6
   PubMed Web of Science ®Google Scholar
• Dougados M., van der Liden S., Juhilin R., Hiutfeldt B., Amor B., Calin A., et al. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 1991; 34: 1218–27
   PubMed Web of Science ®Google Scholar
• Wanders A. J. B., Landewè R. B. M., Spoorenberg A., Dougados M., van der Linden S., Mielants H., et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis ?. Arthritis Rheum 2004; 50: 2622–32
   PubMed Web of Science ®Google Scholar
• Anderson J. J., Baron G., van der Heijde D., Felson D. T., Dougados M. Ankylosing spondylitis assessment group preliminary definition of short term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 1876–86
   PubMed Web of Science ®Google Scholar
• Braun J., Pharm T., Sieper J., Davis J., van der Linden S. J., Dougados M., et al. International ASAS consensus statement for the use of anti‐tumor necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62: 817–24
   PubMed Web of Science ®Google Scholar
• Brandt J., Listing J., Sieper J., Rudwaleit M., van der Heijde D., Braun J. Development and preselection of criteria for short term improvement after anti‐TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1438–44
   PubMed Web of Science ®Google Scholar
• Garrett S., Jenkinson T., Kennedy G., Whitelock H., Gaisford P., Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286–91
   PubMed Web of Science ®Google Scholar
• Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187–93
   PubMed Web of Science ®Google Scholar
• Feagan B. G., Fedorak R. N., Irvine E. J., Wild G., Sutherland L., Steinhart A. H., et al. A comparison of methotrexate with placebo for maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342: 1627–32
   PubMed Web of Science ®Google Scholar
• Jahnsen J., Falch J. A., Mowinckel P., Aadland E. Bone mineral density in patients with inflammatory bowel disease: a population‐based prospective two‐years follow‐up study. Scand J Gastroenterol 2004; 39: 145–53
   PubMed Web of Science ®Google Scholar
• Korelitz B. I., Adler D. J., Mendelsohn R. A., Sacknoff A. L. Long‐term experience with 6‐mercaptopurine in the treatment of Crohn's disease. Am J Gastroenterol 1993; 88: 1198–205
   PubMed Web of Science ®Google Scholar
• Friedman S., Marion J. F., Scherl E., Rubin P. H., Present D. H. Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis 2001; 7: 1–7
   PubMed Web of Science ®Google Scholar
• Wei J. C., Chan T. W., Lin H. S., Huang F., Chou C. T. Thalidomide for severe refractory ankylosing spondylitis: a 6‐months open‐label trial. J Rheumatol 2003; 30: 2627–31
   PubMed Web of Science ®Google Scholar
• Wasserteil V., Bruce S., Sessoms S. L., Guntupalli K. K. Pyoderma gangrenosum treated with hyperbaric oxygen therapy. Int J Dermatol 1992; 31: 594–6
   PubMed Web of Science ®Google Scholar
• Breedveld F. C., Emery P., Keystone E., Patel K., Furst D. E., Kalden J. R., et al. Infliximab in early active rheumatoid arthritis. Ann Rheum Dis 2004; 63: 149–55
   PubMed Web of Science ®Google Scholar
• van der Heijde D., Dijkmans B., Geusens P., Sieper J., De Woody K., Williamson P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis. Arthritis Rheum 2005; 52: 582–91
   PubMed Web of Science ®Google Scholar
• Reguerio M., Valentine J., Plevy S., Fleisher M. R., Lichtenstein G. R. Infliximab for the treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1821–6
   PubMed Web of Science ®Google Scholar
• Braun J., Sieper J. Therapy of ankylosing spondylitis and the other spondyloarthropatides: established medical treatment, anti‐TNF‐therapy and other novel approaches. Arthritis Rheum 2002; 4: 307–21
   Google Scholar